CRISM Therapeutics Corporation

CRTX

VGG042401262

Pharmaceuticals

Delayed London S.E. Other stock markets 07:59:59 17/07/2024 BST			5-day change	1st Jan Change
13.5 ^GBX	0.00%		-6.90%	-6.25%

07-04	Crism Therapeutics Affirms Plan to File Clinical Trial Application for Lead Product in H2	MT
07-03	Crism flags contract talks, reacts to share price surge	AN

Amur Minerals : Directors Dealing

January 23, 2019 at 12:39 am

Share on Google Plus

Share on Facebook0 shares on Facebook

Amur Minerals Corporation ('Amur' or the 'Company'), the nickel-copper sulphide mineral exploration and resource development company focused on the far east of Russia, is pleased to announce that the Directors and Executive Management have yesterday bought 145,435 ordinary shares of the Company at a price of 3.4 pence per share as part of the Director and Executive Share Purchase Programme announced on 17 April 2018.

Attachments

Original document
Permalink

Disclaimer

Amur Minerals Corporation published this content on 22 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 January 2019 00:38:01 UTC

Latest news about CRISM Therapeutics Corporation

Crism Therapeutics Affirms Plan to File Clinical Trial Application for Lead Product in H2	07-04	MT
Crism flags contract talks, reacts to share price surge	07-03	AN
Crism has first day of trade on AIM after name change, buy	05-31	AN
Amur Minerals confirms Extruded buy, name change and board shake-up	05-29	AN
Amur Minerals agrees reverse takeover of Extruded Pharma	05-13	AN
Amur Minerals Signs Reverse Takeover Deal With Extruded Pharmaceuticals	05-13	MT
Amur Minerals Corporation executed a share and purchase agreement to acquire Extruded Pharmaceuticals Ltd for £5.5 million.	05-12	CI
Amur Minerals swings to profit in 2023 as costs fall	05-10	AN
Amur Minerals Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	05-10	CI
EARNINGS AND TRADING: Impairment charge pushes Quartix into the red	03-04	AN
Amur Minerals Advances Reverse Takeover Deal	03-04	MT
Amur Minerals reports widened interim loss as reviews opportunities	25/09/23	AN
Amur Minerals Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	25/09/23	CI
Amur Minerals Corporation Announces Special Dividend	25/09/23	CI
Tintra receives bid approach; NCC trading in line	07/09/23	AN
FTSE 100 Closes Up 0.21% on Pound Weakness	07/09/23	DJ
UK Inflation Expectations Fall, Boosting Prospects for BOE Rate Pause	07/09/23	DJ
UK Gilt Yields Fall on Rising Expectations of a BOE Rate Pause	07/09/23	DJ
FTSE 100 Falls After Weak Performance in Asian Markets	07/09/23	DJ
Amur Minerals Shares Cease Trading on London Bourse's AIM Submarket	07/09/23	MT
Amur Minerals Notes AIM’s Reverse Takeover Requirement	15/08/23	MT
FTSE 100 Closes Down as Investors Driven into Risk-Off Mood	08/08/23	DJ
Sterling Likely to Fall in Longer Run as Markets Overestimate Rate Prospects	08/08/23	DJ
Amur Minerals ends discussions over possible Ascent Resources takeover	08/08/23	AN
FTSE 100 Edges Lower as Miners Fall After Weak China Trade Data, Glencore Earnings	08/08/23	DJ

Chart CRISM Therapeutics Corporation

Duration

Period

More charts

Company Profile

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

Sector

Pharmaceuticals

Calendar

25/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRISM THERAPEUTICS CORPORATION	-6.25%	1.52M
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+36.08%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+15.97%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B